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Summary 
The screening programme for 2015 focused on the occurrence of selected pharmaceuticals 
and hormones in wastewater from hospitals, wastewater treatment works (WWTW) influent, 
effluent and sludges as well as in surface water, sediment and biota in Oslofjord and Lake 
Mjøsa. 
 
Wastewater effluent from three Norwegian hospitals was shown to contain elevated loads of 
selected pharmaceuticals (i.e. amiloride, amitriptyline, amlodipine, atorvastatin, 
azithromycin, ciprofloxacin, clarithromycin, diclofenac, fexofenadine, hydrochlorothiazide, 
lidocaine and simvastatin). Typically the overall contribution from hospitals, based on the 
median daily loads, to the receiving wastewater treatment works was < 0.28% for Ullevål, 
<10% for SI Hamar and <6% or UNN Tromsø. 
 
Treated wastewater from four different WWTWs was shown to contain elevated loads of 
selected pharmaceuticals. Median daily loads were as high as 2.4 x 106 mg day-1 for certain 
pharmaceuticals (i.e. ciprofloxacin and fexofenadine). Effluent median loads of certain 
pharmaceuticals (i.e. atorvastatin, ciprofloxacin, diclofenac) and hormones were reduced 
when compared to influent loads, while median daily loads of other pharmaceuticals (i.e. 
amiloride, amitriptyline, azithromycin, clarithromycin, fexofenadine, lidocaine, simvastatin) 
were higher or similar in the treated effluent than influent. 
 
Median sludge concentrations ranged from between <2.5 and 415 ng g-1 with the following 
selected pharmaceuticals detected; amitriptyline; azithromycin, clarithromycin, 
fexofenadine, lidocaine. Hormone sludge concentrations were typically low (<1 ng g-1). 
 
Few residues of the discharged pharmaceuticals were detected in surface water, sediment 
and biota samples from the recipients of Oslofjord and Lake Mjøsa. 
 
Histopathological analysis of gonads and plasma vittellogenin levels in cod and trout gonads 
from Oslofjord and Lake Mjøsa respectively showed no effects attributable to the low levels 
of steroid hormones being discharged from WWTWs. 
 
The overall risk to the Norwegian aquatic environment from inputs of the selected 
pharamceuticals studied in this report is low with the levels determined below published EQS 
and PNEC values. For example, the EU Watch List pharmaceutical diclofenac and hormones E2 
and EE2 were below the EQS. The risks to agricultural soils from the levels determined in 
sludges was also deemed to be low, however the absence of PNECSoil for amitriptyline and 
fexofenadine suggests that further work should be performed on these two pharmaceuticals 
with respect to their occurrence. 
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Sammendrag 
Screeningsprogrammet for 2015 fokuserte på forekomsten av utvalgte legemidler og hormoner 
i avløpsvann fra sykehus, vannrenseanleggs innløp, avløp og slam samt i overflatevann, 
sediment og biota i Oslofjorden og Mjøsa.  
 
Avløpsvannet fra tre norske sykehus viste seg å inneholde forhøyede mengder av utvalgte 
legemidler (dvs. amilorid, amitriptylin, amlodipin, atorvastatin, azitromycin, ciprofloksacin, 
klaritromycin, diklofenak, feksofenadin, hydroklortiazid, lidokain og simvastatin). Det 
samlede bidraget til de mottagende renseanleggene, basert på median av daglige mengder, 
var vanligvis <0,28% for Ullevål, <10% for SI Hamar og <6% for UNN Tromsø. 
 
Behandlet avløpsvann fra fire ulike renseanlegg viste seg å inneholde høye mengder av 
utvalgte legemidler. Median daglige mengder var så høye som 2.4 x 106 mg dag-1 for visse 
legemidler (dvs. ciprofloksacin og feksofenadin). Medianmengden av visse legemidler (dvs. 
atorvastatin, ciprofloksacin, diklofenak) og hormoner i avløpsvann var redusert sammenlignet 
med det ubehandlede vannet, mens median daglig mengde av andre legemidler (dvs. 
amilorid, amitriptylin, azitromycin, klaritromycin, feksofenadin, lidokain, simvastatin) i det 
behandlede avløpsvannet var høyere eller lik innløpet. 
 
Mediankonsentrasjoner i slam varierte fra mellom <2.5 og 415 ng g-1 med de følgende 
detekterte legemidler: amitriptylin; azitromycin, klaritromycin, feksofenadin, lidokain. 
Konsentrasjoner av hormoner i slam var vanligvis lave (<1 ng g-1). 
Få rester av de utslipte legemidlene ble oppdaget i overflatevann, sediment og biotaprøver 
fra resipientene i Oslofjorden og Mjøsa. 
 
Histopatologiske analyser av gonadene og plasma vittellogenin-nivåer i torske- og 
ørretgonader fra Oslofjorden og Mjøsa viste henholdsvis ingen effekter som kan tilskrives de 
lave nivåene av steroidhormoner som slippes ut fra vannrenseanleggene. 
Den samlede risikoen for det norske vannmiljøet fra tilførsel av legemidler er lav, med 
nivåene fastsatt under de publiserte EQS og PNEC-verdiene. For eksempel var EU Watch list-
legemidlet diklofenak og hormonene E2 og EE2 under EQS. Basert på de fastslåtte verdiene 
for nivåene i slam ble også risikoen for landbruksjord vurdert som lav, men fraværet av 
SoilPNEC for amitriptylin og feksofenadin viser at videre arbeid bør gjøres på forekomsten av 
disse to legemidlene. 
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1. Background and Introduction 
1.1 General 
The Norwegian Environment Agency in 2015 selected two groups of compounds for target 
analysis for inclusion in Part 1 of its annual screening programme. These were 
pharmaceuticals and hormones. The objective of the project was to establish the occurrence 
of these chemicals in the Norwegian marine and freshwater environments, with particular 
focus on their sources potential to bioaccumulate. Additional focus was also placed on 
hospitals as direct sources of pharmaceutical residues to wastewater treatment works 
(WWTW) and WWTWs as point sources of pharmaceuticals to the Norwegian aquatic 
environment. The pharmaceuticals and hormones were selected for screening as they have 
been identified as potentially problematic compounds due to their extensive use and the 
intrinsically active properties. The European Union has started to look at the regulation of 
pharmaceuticals in the environment and in order to initiate this work in Norway there is a 
need for further environmental occurrence data and establish whether pharmaceuticals and 
hormones are potentially having an adverse environmental impact. 
   
The pharmaceuticals and hormones selected, their uses, and previous occurrence in Noridc 
samples are summarised in Table 1. Of the pharmaceuticals selected, amiloride, amlodipine, 
amoxicillin, azithromycin, candesartan, ciprofloxacin, clarithromycin, diclofenac, 17β-
estradiol, 17α-ethinylestradiol, hydrochlorothiazide, ibuprofen, levonorgestrel, 
sulfamethoxazole had previously been included in screening studies in one or more Nordic 
country (Table 1). Amitriptyline, atorvastatin, chloramphenicol, fexofenadine, gliclazide, 
lidocaine, ramipril and simvastatin were included in a Nordic screening study for the first 
time. 
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Table 1. Pharmaceuticals selected for screening, their uses and previously reported levels in Nordic screening studies (TemaNord 
2012:519) 
Pharmaceutical  CAS No.  Use Concentrations in various matrices 
   
WWTW 
influent 
(ng L-1) 
WWTW 
effluent 
(ng L-1)  
Hospital 
WW  
(ng L-1) 
Surface 
waters 
(ng L-1)  
Sludge  
(ng g-1) 
Sediment (ng g-1) Biota (ng g-1) Country 
Amiloride 2016-88-8 
Potassium-sparing diuretic 
used for treating 
hypertension 
Nd-287 Nd-217 Nd-8 53-552 4-57 Nd-0.9  Faroe Islands, 
Greenland & 
Iceland 
Amitriptyline 50-48-6 
Serotonin-ephinephrine 
reuptake inhibitor used 
for treating mental illness 
        
Amlodipine 88150-42-9 
Calcium channel blocker 
used for treating 
hypertension and 
coronary artery disease 
Nd-247 Nd-319 Nd-273 Nd-18 Nd-286 Nd-1.5 No data Denmark, Faroe 
Islands, Greenland 
& Iceland 
Amoxicillin 26787-78-0 
Antibiotic used against a 
number of bacterial 
infections 
Nd Nd Nd Nd 
Nd Nd Nd 
Norway & Sweden 
 
 
Atorvastatin 
134523-00-
5 
Lipid-lowering agent used 
for treating dyslipidemia 
and to prevent 
cardiovascular disease 
        
Azithromycin 83905-01-5 
Antibiotic used against a 
number of bacterial 
infections 
Nd-44 Nd-27  Nd-16 Nd-6  Nd Sweden 
Candesartan 
139481-
597 
Angiotensin II receptor 
antagonist used for 
treating hypertension 
Nd-57 Nd-111 Nd-251 Nd-5 Nd-50 Nd  Faroe Islands & 
Iceland 
 
Chloramphenicol 56-75-7 
Antibiotic used against a 
number of bacterial 
infections when safer 
antibiotics cannot be 
used. Rapid inactivation 
in nature. 
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Pharmaceutical  CAS No.  Use Concentrations in various matrices 
Ciprofloxacin 85721-33-1 
Antibiotic used against a 
number of bacterial 
infections 
Nd-
2,920 
Nd-
1,320 
Nd-
101,000 
Nd.-160 100-7,400 Nd-130 Nd-9 Finland, Norway & 
Sweden 
 
Clarithromycin 81103-11-9 
Antibiotic used against a 
number of bacterial 
infections 
Nd-620 Nd-780  Nd-
11,000 
 Nd-5 Nd 
 
 
Sweden 
Diclofenac 15307-86-5 
NSAID used to treat 
inflammations and to 
reduse pain and fever 
Nd-
9,700 
Nd-
3,900 
Nd-0.6 Nd-880 Nd-560 Nd-3.5 Nd Faroe Islands, 
Finland, 
Greenland, 
Iceland & Sweden 
17β-estradiol 50-28-2 Sex hormone 
Nd-465 Nd-357 Nd-358 Nd-1.2 Nd-310 Nd-130 Nd Denmark, Faroe 
Islands, Greenland 
& Iceland, 
Norway, Sweden 
17α-ethinylestradiol 57-63-6 Contraceptive pill 
Nd-54 Nd-40 Nd-20 Nd-3.7 Nd-6800 Nd Nd-0.9 Denmark, Faroe 
Islands, Greenland 
& Iceland, 
Norway, Sweden 
Fexofenadine 83799-24-0 
Second-generation 
antihistamine used to 
treat allergy symptoms  
        
Gliclazide 21187-98-4 
A sulfonylurea used for 
treating hyperglcemia 
        
Hydrochlorothiazide 58-93-5 
Diuretic used for treating 
hypertension and swelling 
due to fluid build up 
Nd-90 22-984 6-345 Nd Nd-168 Nd  Faroe Islands, 
Greenland, 
Iceland 
Ibuprofen 15687-27-1 
NSAID used to treat 
inflammations and to 
reduse pain and fever 
Nd-
16,000 
Nd-
7,800 
3-
12,100 
Nd-900 Nd-22,000 Nd-2.8 Nd Denmark, Faroe 
Islands, Greenland 
& Iceland, 
Norway, Sweden 
Levonorgestrel 797-63-7 Synthetic progestogen  
Nd Nd Nd Nd Nd Nd Nd Sweden 
Lidocaine 137-58-6 
Anaesthetic used to numb 
tissue in a spesific area 
and to treat ventricular 
tachycardia 
        
Ramipril 8733-19-5 
Angiotensin-converting 
enzyme (ACE) inhibitor 
used to treat 
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Pharmaceutical  CAS No.  Use Concentrations in various matrices 
hypertension and 
congestive heart failure 
Simvastatin 79902-63-9 
Statin used to treat 
dyslipidemia and to 
prevent atherosclerosis-
related complications 
such as stroke and heart 
attacks 
        
Sulfamethoxazole 723-46-6 
Antibiotic used against 
bacterial infections such 
as urinary tract 
infections, bronchitis and 
prostatitis 
Nd-
1,500 
Nd-290 Nd-
6,600 
Nd-620 Nd-151 Nd-16 Nd-13 Denmark, Norway, 
Sweden 
Nd- Not detected. Blank- no reported data. 
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2. Materials and Methods 
2.1 Sample description and collection 
2.1.1 Wastewater treatment plants (WWTWs) 
Four wastewater treatment works (WWTW), representative of different sized populations and 
influent sources, were selected for investigation. 
  
Vestfjorden avløpsselskap (VEAS) at Slemmestad is Norway´s largest WWTW receiving 
municipal wastewater from a population of around 550,000. The plant annually receives 
between 100-110 x 106 m3 of wastewater that is treated mechanically, chemically and 
biologically (post-denitrification). The sludge is treated by anaerobic digestion and drying. 
Treated effluent is discharged into Oslofjord at a depth of approximatley 50 m. 
  
HIAS WWTW receives wastewater from approximatley 52,000 people from the municipalities 
of Hamar, Løten, Ringsaker, and Stange. The plant is located at Ottestad on Lake Mjøsa with 
the discharge point at a depth of 15 m around 250 m from the shore. Wastewater is treated 
mechanically, biologically (not N removal) and chemically. The sludge is treated by thermal 
hydrolysis (Cambiprocess at 160°C) prior to anaerobic digestion at 38°C. 
 
Rambekk WWTW in the municipality of Gjøvik receives wastewater from approximately 
17,900 people plus industry (11,600 PE). The plant is located on the shore of Lake Mjøsa with 
the discharge point at a depth 7 m. The wastewater is treated mechanically and chemically. 
The resulting sludge is treated together with external sewage sludge from up to eight 
municipalities in the region by mesophilic (34-39°C) anaerobic digestion at a pH of 
approximately 7, followed by drying. 
 
Breivika WWTW in Tromsø municipality receives domestic wastewater from a total of 2,850 
households and the University hospital Nord-Norge (UNN Tromsø) (total of ca. 18,000 people 
equivalents). The wastewater is treated by simple screening (Salsnes Filter SF 6,000 with 0.35 
mm mesh size) and the plant has a capacity of 18,700 person equivalents. The sludge that is 
removed is dewatered in a screw press and sent to Balsfjord municipality (Stormoen) for 
windrow composting. The treated wastewater is discharged at 30 m depth and ca. 300 m out 
into the Tromsøy strait. 
 
WWTW sampling 
Staff at the respective plants collected all of the WWTW samples. They were kindly asked not 
to use plastic gloves during samples and to avoid the use of personal care products. Twenty-
four hour composite effluent samples were collected by means of an automatic sampling 
equipment already found at the WWTWs for routine monitoring. The effluent samples were 
collected in clean glass bottles (1x 2.5 L bottle, 1x 0.5 L bottle and 2x 0.25 L bottles, where 
the three small bottles were top-filled) and shipped to NIVA. 3 x 0.25 L bottles containing 
Imsdals water were opened during sampling on one of the sampling days and used as a field 
blank. Sludge samples were collected on the same days as the effluent samples using a 
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procedure based on the Mattilsynet guideline for the sampling of sludge, compost and other 
waste-based fertilizer products. Five core samples of mixed sludge were collected from each 
facility. Each mixed sample was transferred to 4 glass sample jars using pre-washed stainless 
steel equipment provided by NIVA. 
 
2.1.2 Hospitals 
Three hospitals were selected for this study: 
 
Ullevål University Hospital is one of the largest hospitals in Oslo. It has approximately 45,000 
admittances and 400,000 patient consultations annually covering a broad spectrum of somatic 
illnesses, including oncology and psychiatry patients. The hospital discharges untreated 
effluent to VEAS WWTW. 
SI Hamar Hospital is the main hospital for a population of almost 85,000 people in the Hamar, 
Stagne, Løten and Ringasker region. Effluent is discharged untreated to HIAS WWTW. 
The University Hospital of Northern Norway (UNN Tromsø) is based in Tromsø. The hospital 
offers treatment for a broad spectrum of somatic illnesses, as well as having specialist 
departments for oncology and psychiatry patients from the whole of Northern Norway. The 
hospital effluent constitutes approximately a 10% of the influent to Breivika WWTW. 
 
Hospital effluent sampling 
Ullevål University Hospital 
An automatic sampler (ISCO 6712; provided by Oslo VAV) was mounted in a manhole (No. 
210237) in a part of the sewer that included only, and most probably the main part of, the 
wastewater coming from the hospital area (See Figure 1). An ISCO 2150 flowmeter (provided 
by NIVA) was mounted in the same manhole and was coupled to the autosampler to provide 5 
x flow-proportional 24-hour composite samples from 50 ml sub-samples collected every 30 m3 
wastewater. 2 L of the sample was transferred to 2x 1 L plastic bottles and brought directly 
to NIVA for freezing. 
 
   
Figure 1. Automatic sampler and flowmeter mounted in manhole at Ullevål hospital. 
 
SI Hamar 
An automatic sampler (ISCO 6700; provided by NIVA) was mounted on top of a manhole in a 
part of the sewer that included only, and the main part of, the wastewater coming from the 
hospital area. An ISCO 2150 flowmeter (provided by NIVA) was mounted in the same manhole 
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and was coupled to the autosampler to provide 5x flow-proportional 24 hour composite 
samples from 50 ml sub-samples ollected every 0.5 m3 wastewater. 2 L of the sample was 
transferred to 2x 1 L plastic bottles provided by NIVA and stored frozen until shipment to 
NIVA.   
 
UNN Tromsø 
An automatic sampler (ISCO 6700; provided by NIVA) was mounted in a manhole (S302) 
upstream a V-shaped overflow (to assure high enough water level in the sewer even during 
nights) in a part of the sewer that included only, but all, wastewater coming from the 
hospital area. The sampler collected 5x 24-hour composite samples from 50 ml sub-samples 
collected every 8 min, preferentially during dry-weather conditions. 2 L of the sample was 
transferred to 2x 1 L plastic bottles provided by NIVA and stored frozen until shipment to 
NIVA. A flow meter (ISCO 2150; provided by Tromsø municipality) was mounted through a 
manhole upstream of the autosampler. This stopped working after the three first samples. 
The flows during the two last sampling days were estimated based on flow measurements 
done on days with similar precipitation patterns. 
 
2.1.3 Inner Oslofjord 
Surface water 
Water was collected at five stations with a Niskin water sampler, at 10 meters depth. The 
water samples were taken at the same stations as the sediment samples. The water sample 
was transferred to a 2.5 litre bottle and stored cold until analysis. 
 
Sediment 
Sediment samples were collected at five stations along a transect from close to the discharge 
diffuser from the VEAS WWTW and southward in the deep-water channel of Oslofjord (Figure 
2). On the west side of the fjord, the tidal current runs in a southerly direction and is split by 
a vortex near the middle of the fjord south of Søndre Langåra. There are also currents 
through Ristsundet on the east side of Håøya, and one current on the west side of Håøya 
(Gråøyrenna). On rising tide most of the current flows on the east side of Håøya. Sediment 
stations were placed in the deep channel on both sides of Håøya. The sediment stations were 
on approximately same depths. Sediment was collected with a stainless steel Van Veen grab. 
One sample of the top 2 cm of the sediment was collected from each station. Each sample 
was a mixed composite from three grabs. 
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Figure 2. Map of the sediment stations in the Oslofjord. 
 
Atlantic cod and herring 
Atlantic cod (Gadus morhua) and herring (Clupea harengus) were caught by trawling from the 
research vessel F/F Trygve Braarud during 19th of August 2015. The cod were caught in the 
area between Askerlandet and Steilene in the Inner Oslofjord and ranged in size from 1.1 to 
5.8 kg. Cod was killed with a blow to the head with a priest (club), and then dissected on-
board. Individual samples of liver were removed for chemical analysis and stored in heat-
treated (500 °C) glass containers sealed with heat-treated aluminium foil underneath the lids.  
Samples were stored frozen (-20o C) until analysis. 
 
Blood samples were taken from the cod with heparinized syringes. Plasma was separated with 
a centrifuge, and then the samples were kept in liquid nitrogen until transfer to -80°C freezer 
at NIVA. Samples of gonads were dissected out and put in cassettes and then put into two 
kinds of fixation solutions (Baker’s and Davidson’s fixation solutions). Gonad samples were 
then sent to IRIS for pathological analysis. 
 
Individual samples were made of five herring. The samples consisted of whole fish without 
head and spine. 
Shrimp 
Northern shrimp (Pandalus borealis) were caught by trawling. The shrimps were peeled and 
split into 5 bulk samples. Each sample comprised of between 50 and 60 individual shrimps. 
Blue mussel 
Blue mussel (Mytilus edulis) was sampled at five stations in the Oslofjord. The blue mussels 
were sampled from stations nearby the discharge from VEAS, and on stations on increasing 
distance from the discharge in southward direction (Figure 3; Table 2).  
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Figure 3. Blue mussels were sampled at five stations (●) in the Oslofjord. 
 
 
 
 
 
 
 
 
VEAS 
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Table 2. Blue mussel stations with distance from the VEAS WWTW 
Blue mussel sampling stations Distance from VEAS 
B1 Sjøstrand 900 meters north 
B2 Slemmestad 1.3 km south 
B3 Nærsnesbukta 3.2 km south 
B4 Håøya, Bjørnhodebukta 9.2 km south 
B5 Sætre, Skålevika 12.7 km south 
 
One bulk sample was made from each station. Each sample comprised of soft tissue from 20 
blue mussels (length 6-8 cm).  
 
2.1.4 Lake Mjøsa 
Surface water 
Water was collected at five stations with a Ruttner water sampler, at 15 meters depth (26th 
May 2015). The water samples were taken at the same stations as the sediment samples. Each 
water sample was transferred to two l litre PE bottles and stored cold until analysis. 
Sediment 
Five pooled samples of sediment were taken along a gradient from the discharge point to HIAS 
and south (26th May 2015). Each pooled sample consisted of three individual subsamples 
taken from the upper 0-2 cm sediment layer at a water depth of 25–35 m. We used a gravity 
corer with a core tube and a retractable sediment stopper in stainless steel. The samples 
were transferred to heat-treated (500 °C) glass containers sealed with heat-treated 
aluminium foil underneath the lids. The core tube and other sectioning equipment used were 
thoroughly cleaned with acetone and cyclohexane (HPLC grade) before use, and direct hand 
contact with the sampling matrix was avoided. They samples were stored frozen (-20 °C) until 
analysis. 
Fish 
From Lake Mjøsa, between 11. – 30. August 2015, we collected the following species of 
pelagic fish: brown trout (Salmo trutta), smelt (Osmerus eperlanus) and vendace (Coregonus 
albula). Smelt and vendace were caught with gillnets, deployed in the area around the outlet 
of discharge pipe of the HIAS sewage treatment plant, at a depth of about 20 – 35 m, whereas 
brown trout were caught north of the town of Gjøvik at a depth of 5 –20 m. The smelt were 
mainly small-bodied planktivorous individuals, but a few larger cannibalistic individuals were 
also included. 
 
Smelt and vendace were taken out of the nets as they were hauled, instantly killed with a 
short blow to the head, wrapped in clean aluminium foil, kept cool and transported to a 
freezer (-20 °C). Before freezing the aluminium foil wrapped fish were put in polyethylene 
bags. At no time were the fish allowed to be in contact with plastics or other potentially 
contaminated surfaces. The time between catch and transfer to the freezer took no longer 
than 4 hours. 
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The brown trout were transferred to a water filled container after they were taken out of the 
nets, transported alive to the shore where a bench with the necessary tools and equipment 
for sampling of blood and histological samples of gonads and liver were waiting. The 
biological samples were prepared in accordance with a Standard Operating Procedure. From 
each fish a blood sample was taken from the caudal vein with a syringe pre-treated with 
heparin and aprotinin, centrifuged with subsequent removal of supernatant before snap-
frozen in liquid nitrogen. A liver tissue sample was dissected and snap-frozen in liquid 
nitrogen, whereas a gonad sample was transferred to a cassette and formalin fixated. The fish 
was then wrapped in aluminium foil and transported to a freezer (-20°C) for later dissection 
and preparation of the muscle samples for chemical analyses. 
 
Before preparing the pelagic fish muscle samples, they were thawed and the total length and 
weight recorded (Table 3). The fish were then scraped clean of mucus with a solvent washed 
knife and placed on a cutting board covered with solvent rinsed aluminium foil. A solvent 
cleaned set of stainless steel dissection tools was used for each fish. The sagittal otoliths 
were dissected and sex and maturity determined following opening of the abdomen. Samples 
of lateral skeleton muscles were then dissected and transferred to heat-treated (500 °C) glass 
containers sealed with heat-treated aluminium foil placed underneath the lids. The samples 
were then frozen (-20°C) and sent for homogenization before analysis. Five pooled samples 
were prepared for smelt and vendace, respectively, to obtain sufficient material for chemical 
analysis, whereas 10 individual samples were prepared for brown trout.  
 
All personnel involved in fieldwork and sample preparation avoided the use of personal care 
products for at least 24 hours prior to any activity. Dissection and sample preparation was 
performed outside in a non-urban area. All dissection equipment and aluminium foil that 
could have direct contact with the samples was cleaned with acetone and cyclohexane (HPLC 
grade) before use, and direct hand contact with the sampling matrix was avoided. 
 
Table 3. Mean length and weight of the studied fish. Pooled samples 
were made for smelt and vendace. 
   Length (cm) Weight (cm) 
Species Sample 
No. 
N Mean Std Dev Mean Std Dev 
Smelt 1 5 21.7 0.6 55.6 9.2 
  2 7 17.2 1.3 29.1 7.2 
  3 8 15.8 0.2 24.3 1.5 
  4 11 14.7 1.0 18.0 4.1 
  5 40 11.4 0.6 10.7 1.3 
Vendace 1 4 21.4 0.9 75.5 4.7 
  2 3 21.7 0.4 74.3 6.5 
  3 4 20.8 0.9 73.8 11.3 
  4 3 21.4 1.1 75.3 10.5 
  5 4 20.7 0.4 69.8 3.6 
Brown 
trout 
1:10 10 64.8 13.1 3569 2321 
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Mysis and zooplankton 
Samples of the opossum shrimp Mysis relicta and zooplankton were sampled with horizontal 
net hauls. Epipelagic zooplankton, consisting mainly of the cladocerans Daphnia galeata and 
Bosmina longispina together with the copepod Eudiaptomus gracilis, were collected at a 
depth of 3–5 m, whereas Mysis were collected at a depth of 70–110 m (this is a diurnal vertical 
migrating Mysida, mainly feeding in the epipelagic zone during night-time). The zooplankton 
net used were made of nylon mesh (single strand thread, mesh size: 500 µm), equipped with 
a brass cup with a brass mesh, and with an opening diameter of 1 m. 
 
Mysis were separated from copepods in the hypopelagic samples by filtering the samples 
through a sieve (mesh of stainless steel strands) while flushing gently with water from the 
lake and handpicking with tweezers. All filtering and separation of samples were done in the 
boat immediately after net hauling. The samples were kept on the same type of cleaned class 
jars as the fish, held cool on board until they could be transferred to a freezers (-20°C) no 
more than 8 hours after sampling. All equipment (glass or metal) and aluminium foil that 
could be in direct contact with the samples after they were transferred from the net were 
cleaned with acetone and cyclohexane (HPLC grade) before use, and direct hand contact with 
the samples was avoided. We prepared 5 samples each of Mysis and epipelagic zooplankton. 
 
 
 
 
 
 
 
 
Figure 4. Map showing Lake Mjøsa, the catch sites (blue star: smelt and vendace; red star: brown trout; Mysis and 
zooplankton: green star) and sediment/water sampling sites (red circles). The location coordinates are given in Table 
4 
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Table 4. Coordinates for the Lake Mjøsa water, sediment and biota sampling stations 
Station Date Depth (m) UTM 33E UTM 33 N °E °N 
Sediments/water       
St-1 26.05.2015 sed.: 35, water: 15 286400 6743600 11.059 60.766 
St-2 26.05.2015 sed.: 25, water: 15 285941 6742150 11.075 60.759 
St-3 26.05.2015 sed.: 25, water: 15 285932 6740684 11.072 60.744 
St-4 26.05.2015 sed.: 25, water: 15 286479 6739302 11.084 60.732 
St-5 26.05.2015 sed.: 25, water: 15 287021 6737370 11.096 60.715 
Fish       
St-1 11.08.15 20–35 286400 6743600 11.059 60.766 
St. Gjøvik 13.-30.08.15 10–20 265100 6750000 10.680 60.816 
Mysis  10.-13.08.14 70–110 284000 6735000 11.04 60.69 
Zooplankton 13.09.15 3-5  284000 6735000 11.04 60.69 
 
2.2 Chemical analysis 
2.2.1 Pharmaceuticals  
Biota (approx. 1 g wet weight), and sediment and sludge (exactly 0.5 g dry weight) aliquots 
were taken. Deuterated internal standard was added to each aliquot before the addition of 1 
ml 0.1 M zinc sulfate. 1 min of vortex mixing resulting in cell lysis. 4 ml ACN added to further 
precipitate proteins and extract the pharmaceuticals by further vortexing. 
 
1 g QuECHERS (80-85% Magnesium Sulfate and 15-20 % Sodium Acetate; Waters, Sweden) 
extraction powder was added to each extract and mixed by vortex for 1 min. The samples 
were centrifuged at 2500 rpm for 6 minutes and the supernatent (300 µL) transferred to 
deep-well 96-well plate (2 ml). 600 µL of ultrapure water was added to each well. The well 
plates were centrifuged at 3500 g for 10 minutes. The calibration standard were also 
transferred to 96-well plate and diluted as per samples. The samples were then analysed on a 
ultra performance liquid chromatograph coupled to a high resolution mass spectrometer. The 
uncertainty (relative standard deviation; RSD) of the concentrations determined using this 
method is estimated to be around 25%. 
 
   
2.2.2 Hormones 
Aliquots of freshwater (approx. 450 ml) and effluent (approx. 200 ml) were liquid/liquid 
extracted with dichloromethane. The dichloromethane was evaporated, the residue 
redissolved in small amount of acetonitrile and split into two aliqots. One was derivatized 
with dansylchloride and used for the determination of estradiol and ethynylestradiol and the 
other was derivatized with perfluoroglutaric anhydride and used for determination of 
levonorgestrel. 
 
Sediment and sludge samples (1-2 g) were extracted with acetonitrile/hexane (50:50). The 
acetonitrile was removed and reduced in volume, divided in 2 and derivatised as with the 
aqueous phase samples. Deuterium labeled hormones were used as internal standards for 
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quantification. The instrument used was LC/MS-MS (Accela liquid chromatograph with TSQ 
Vantage mass-spectrometer). 
 
2.2.3 Biomarkers and pathology 
Vitellogenin analysis 
Vitellogenin (VTG) production was measured through a capture ELISA as previously described 
by Sundt and Björkholm (2011) and Tollefsen et al. (2003), with minor modifications. In brief, 
frozen plasma samples of brown trout (Salmo trutta) and cod (Gadus morhua) were thawed 
on ice and diluted 1:50 - 1:5000 in a coating buffer (50 mM bicarbonate-carbonate buffer, pH 
9.6), followed by dilution of trout VTG (with 3–3000 ng/ ml) and Cod Vtg (0.24-250 ng/ ml) 
(Biosense Laboratories, Bergen, Norway). The diluted samples, buffer blanks and respective 
VTG standard were transferred to a 96-well Maxisorp Nunc-immunoplate (Nunc, Roskilde, 
Denmark) in triplicate, sealed and incubated in the dark at 4C for <16 h. The plates were 
rinsed three times with washing buffer (0.05% Tween-PBS, pH 7.2 (T-PBS)), followed by the 
addition of the blocking solution (2% bovine serum albumin (BSA)-PBS) and incubated for 1 h 
in the dark at room temperature. Following incubation, the plates were rinsed three times in 
T-PBS and a poly-clonal rabbit anti-cod VTG antibody (CS-1, 1:1000x diluted in PBS containing 
1% BSA, Biosense Laboratories, Bergen, Norway) and a mono-clonal mouse anti-salmon Vtg 
antibody (BN-5, 1:6000× diluted in PBS containing 1% BSA, Biosense Laboratories, Bergen, 
Norway) was added in respective plates, followed by incubation at 37C for 2 h. The plates 
were rinsed three times with T-PBS and the secondary antibody goat anti-rabbit IgG (1:3000x 
diluted in PBS containing 1% BSA, Bio-Rad, Herculeas, CA, USA) and goat anti-mouse IgG 
(1:6000x diluted in PBS with 1% BSA, Bio-Rad, Herculeas, CA, USA) were added respectively, 
and incubated at 37C for 1 h. Following incubation, the plates were rinsed five times with T-
PBS and the HRP enzyme substrate (TMB plus2, KEMENTEC diagnostics, Taastrup, Denmark) 
was added to all wells to start the colour development. The plates were incubated in the dark 
at room temperature for 15 min before colour development was stopped with 1 M H2SO4. 
Absorbance was measured at 450 nm using a Versamax microplate reader (Molecular Devices, 
USA). The total amount of VTG protein in the plasma samples was calculated using the known 
amount (ng/ ml) of VTG in respective standards. 
 
Histology 
Histological parameters are commonly used as markers of health status in various fish species. 
The identification of pathologies and diseases are increasingly being used as indicators of 
environmental stress since they provide a definite and ecologically relevant end-point for 
chronic/ sub chronic contaminant exposure. The application of histological markers in fish 
can include measures of reproductive and metabolic condition, and allows for the detection 
of various pathogens that may affect population mortality. The data generated from this type 
of analysis in various organs (i.e. gills, gonads, digestive gland) is helpful in providing 
information for biomonitoring programme (Corbett et al., 2011).  
Histopathological alterations illustrate a definitive endpoint of historical exposure, 
intermediate between initial biochemical changes and reproductive capability and growth 
(Stentiford et al., 2003, Salamat et al., 2013). 
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Histopathology in digestive gland and gill 
10 samples from cod collected from the Oslofjord, and 10 samples from trout collected from 
Lake Mjøsa were analysed. Gonad were dissected by IRIS and placed in histo-cassettes and 
into histological fixative (3.7% formaldehyde) for wax sections. Tissue samples were no 
thicker than 1 cm to ensure proper fixation. Samples were then stored at 4˚C until 
embedding. 
 
Histological sections (3 µm) were prepared at Stavanger University Hospital (SUS). The tissues 
were examined for health parameters related to physiological conditions, inflammatory and 
non-specific pathologies and those associated with pathogen and parasite infections. Gonad 
abnormalities were scored using the criteria suggested by Benly et al. (2008) and Sensini et 
al. (2008). Each alteration was scored according to its severity and frequency (0 = absence of 
alteration, 1 = ≤ 10 % of the histological section showed the alteration, 2 = between 10% and 
50% of the histological section showed the alteration, 3 = between 50% and 100% of the 
histological section showed the alteration). 
 
The presence of parasites and non-specific inflammation were scored as absent (0) or present 
(1). All micrographs were captured using an AxioCam MRc5 (Zeiss) digital camera mounted on 
a Zeiss Axioplan 2 light microscope (Göttingen, Germany). The slides were analysed blind. 
The stage of the gonads was also evaluated. 
 
2.2.4 Support Parameter analysis 
Particle Size Analysis 
Wet sediment was shaken using a mechanical fractionator fitted with < 63 μm sieves. Dry 
weight measurements were used for the particle size calculations. 
 
Sediment TOC 
Freeze dried sediment sample aliquots (0.5-10 mg) were heated in a furnace at 1,800 oC in 
the presence of oxygen free helium. The carbon dioxide gas produced was passed through a 
chromatography column and the total organic carbon was measured.  
 
Water DOC 
Samples (4 ml) were injected into an inorganic carbon chamber and 0.5 ml 21% phosphoric 
acid was added. The inorganic bound carbon from carbonates, bicarbonates and dissolved CO2 
is released to an NDIR detector for CO2 quantification. 
 
Lipid content 
Lipids were calculated gravimetrically following solvent extraction and performed in 
duplicate for each sample. A column packed with an aliquot of the sample (approximately 
0.5-1 g liver or 5 g filet) and sodium sulphate was extracted with 100 ml dichloromethane. 
The solvent extract was then evaporated to dryness and the remaining lipids dried at 110 oC 
to constant weight.  
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δ13C/δ13N ratio analysis 
Samples were dried at 60 oC for 24 hours before grinding to fine powder.  Approx 1 mg of 
sample was combusted in the presence of O2 and Cr2O3 at 1700 oC in a Eurovector element 
analyser. Reduction of NOx to N2 was done in a Cu oven at 650 oC. H2O was removed in a 
chemical trap of Mg(ClO4)2 before separation of N2 and CO2 on a 2 m Porapolt Q GC column. 
The C/N ratio was quantified on the basis of the m/z 44/28 ratio. N2 and CO2 were directly 
injected online to an isotope ratio mass spectrometer (Nu Instruments Horizon) for the 
determination of δ13C and δ13N. The mean stable N-isotope ratios, δ15N, reflects the 
relative trophic position of the organisms. Likewise, the stable C-isotope ratio, δ13C, reflects 
the carbon sources of the organism. A low δ13C/δ13N ratio indicates influence from a pelagic 
food chain whereas a higher ratio indicates a more littoral food chain. We have lipid-adjusted 
all the δ13C-ratios in order to remove the effect of 13C-depleted lipids in the fatty burbot 
samples. 
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3. Results and Discussion 
3.1 Hospital effluent 
3.1.1 Pharmaceuticals 
Twelve of the 19 pharmaceuticals were detected in the hospital effluents from Ullevål, SI 
Hamar and UNN Tromsø (Figure 5). These were amiloride, amitriptyline, amlodipine, 
atorvastatin, azithromycin, ciprofloxacin, clarithromycin, diclofenac, fexofenadine, 
hydrochlorothiazide, lidocaine and simvastatin. The data were transformed to daily loads (mg 
day-1) in order to aid comparison and assess the contribution of hospital effluent to the 
connected WWTW influent load. Multiplying the measured concentrations by the flow of 
effluent achieved this. Loads were calculated for the pharmaceuticals not detected using a 
value of 0.5 x LOD. The median effluent pharmaceutical loads from Ullevål hospital were up 
to 54 mg/day for ciprofloxacin with loads of lidocaine (24 mg day-1) and fexofenadine (21 mg 
day-1) being higher than the other pharmaceuticals, which were typically present at loads of 
<5 mg day-1. Effluent from both SI Hamar and UNN Tromsø also contained elevated loads of 
ciprofloxacin (582 and 41 mg day-1 respectively) and lidocaine (1,093 and 26 mg day-1 
respectively). In general the pharmaceutical loads from all three hospitals was < 5 mg day-1 
with a few exceptions (e.g. atorvastatin and amiloride). This is in the same range as 
previously reported for Norwegian hospitals (Thomas et al., 2007; Langford & Thomas, 2009).   
 
 
3.1.2 Hormones 
E2 and EE2 were detected in all three of the hospital effluents (Figure 6; Figure 7; Figure 8). 
Levonorgestrel was not detected in any of the hospital effluents. Median daily E2 loads were 
typically between 8 and 42 mg day-1 and EE2 between 0.08 and 0.18 mg day-1. 
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Figure 5. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum daily 
loads from hospital effluents from Ullevål, SI Hamar and UNN Tromsø  
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Figure 6. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum daily 
loads of E2 and EE2 for Ullevål hospital effluent and VEAS WWTW influent and effluent 
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Figure 7. Box and whisker plots showing median (n=5), first quartile, third quartile, maximum and minimum daily 
loads of E2 and EE2 for SI Hamar effluent and HIAS WWTW influent and effluent 
 
0	
100	
200	
300	
400	
500	
600	
700	
800	
900	
1000	
SI	Hamar	 HIAS	influent	 HIAS	Effluent	
Lo
ad
	(
m
g/
d
ay
)	
Sample	
E2	
0	
0.1	
0.2	
0.3	
0.4	
0.5	
0.6	
0.7	
0.8	
0.9	
1	
SI	Hamar	 HIAS	influent	 HIAS	Effluent	
Lo
ad
	(
m
g/
d
ay
)	
Sample	
EE2	
Screening programme 2015  |  M-M-597|2016 
27 
 
Figure 8. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum daily 
loads of E2 and EE2 for UNN Tromsø effluent and Breivika WWTW influent and effluent 
 
 
3.2 Wastewater treatment plants  
3.2.1 Pharmaceuticals 
Nine of the 19 pharmaceuticals were detected in either wastewater treatment works influent and/or effluent 
(Table 5). In the figures presented (Figure 5;  
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Figure 9; Figure 10; Figure 11) the concentrations determined have been transformed to loads 
and for compounds detected <LOQ, a value of LOQ x 0.5 has been used. 
 
VEAS WWTW 
Comparison of the median (n=5) pharmaceutical loads in the VEAS influent and effluent samples showed loads of up 
to 2.4 x 106 mg day-1 (ciprofloxacin and fexofenadine;  
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Figure 9). For the other pharmaceuticals analysed the loads were typically <50,000 mg/day. 
Comparison of influent with effluent loads for the detected pharmaceuticals changes in 
concentrations of between 23% (atorvastatin) and 475 % (simvastatin; Table 5). 
 
The contribution in terms of daily loads from Ullevål Hospital to VEAS, based on a comparison 
of the median values was typically < 0.5% for all analysed pharmaceuticals. This compares 
with similar values for most pharmaceuticals in previous studies investigating the inputs of 
pharmaceuticals from Ullevål hospital to VEAS WWTW (Thomas et al., 2007; Langford & 
Thomas, 2009). 
 
Four of the selected pharmaceuticals were detected in sludges from VEAS (Figure 10). 
Amitryptyline was detected at a median concentration of 77 mg kg-1, azithromycin at 60 mg 
kg-1, clarithromycin at a median concentration of 7.7 mg kg-1, fexofenadine at a median 
concentration of 658 mg kg-1and lidocaine <5 mg kg-1. 
 
Table 5. Comparison of the pharmaceutical loads 
in effluent and influent based on median 
concentrations  
Pharmaceutical VEAS HIAS Breivika Rambekk 
Amiloride 109 109 91 95 
Amitriptyline 218 227 101 91 
Amlodipine 100 86 101 100 
Atorvastatin 23 67 104 56 
Azithromycin 177 297 103 100 
Ciprofloxacin 94 88 118 92 
Clarithromycin 188 155 198 100 
Diclofenac 86 194 146 49 
Fexofenadine 157 106 172 114 
Hydrochlorothiazide 100 65 100 800 
Lidocaine 119 37 281 220 
Simvastatin 475 3440 172 575 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Percentage contribution of each pharmaceutical 
from the three selected hospitals to the respective WWTW 
influent based on median loads  
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Pharmaceutical Ullevål SI Hamar UNN Tromsø 
Amiloride 0.05 2.5 0.2 
Amitriptyline 0.04 2.5 0.2 
Amlodipine 0.04 10 0.3 
Amoxicillin 0.04 1.6 0.2 
Atorvastatin 0.03 2.1 0.3 
Azithromycin 0.01 1.6 0.3 
Candesartan 0.04 1.6 0.2 
Chloramphenicol 0.04 1.6 0.2 
Ciprofloxacin 0.05 83 0.5 
Clarithromycin 0.01 6.2 0.1 
Diclofenac 0.05 9.3 0.03 
Fexofenadine 0.03 3.5 0.4 
Gliclazide 0.04 1.6 0.2 
Hydrochlorothiazide 0.04 1.9 0.2 
Lidocaine 0.25 786 5.5 
Ramipril 0.04 1.6 0.2 
Simvastatin 0.28 3.7 0.1 
Sulfamethoxazole 0.04 1.6 0.2 
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Figure 9. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum daily 
loads for VEAS WWTW influent and effluents 
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Figure 10. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum 
concentration of pharmaceuticals and hormones in sludges from VEAS WWTW 
 
HIAS WWTW 
Influent and effluent from HIAS WWTW contained median pharmaceutical loads of up to 
21,600 mg day-1 (atorvastatin). Elevated median loads of ciprofloxacin (11,600 mg day-1) and 
fexofenadine (10,400 mg day-1) were detected in HIAS influent (Figure 11). The difference in 
influent and effluent median daily loads for the detected pharmaceuticals showed a reduction 
in effluent concentration for amlodipine (14%), atorvastatin (33%), ciprofloxacin (12%), 
hydrochlorothiazide (35%) and lidocaine (63%) indicating some degree of removal at the 
WWTW before discharge into Lake Mjøsa (Table 5). For a number of the other compounds the 
median daily loads were greater in the effluent than the influent. For example for 
amitriptyline, azithromycin, clarithromycin, diclofenac and simvastatin there was an increase 
in the median effluent loads when compared with the influent. A possible explanation for this 
may be a high variability in the emission of these particular drugs in the HIAS catchment, 
resulting in a high level of variability in the concentrations measured, or also due to 
deconjugation of pharmaceuticals excreted as their sulphate or glucuronide congregates.  
The contribution in terms of median daily pharmaceutical loads from SI Hamar to HIAS shows 
that the hospital typically contributes around 2% for each pharmaceutical analysed, apart 
from amlodipine (10%), ciprofloxacin (83%), clarithromycin (6%), diclofenac (9%) and 
lidocaine. The contribution is generally higher than Ullevål, however this proportion is clearly 
due to the larger dilution at VEAS from other sources than domestic wastewater. 
Four of the selected pharmaceuticals were detected in sludge from HIAS (Figure 12). 
Amitryptyline was detected at a median concentration of 80 mg kg-1, azithromycin at <30 mg 
kg-1, clarithromycin at a median concentration of 5,6 mg kg-1, fexofenadine at a median 
concentration of 447 mg kg-1and lidocaine 10.9 mg kg-1. 
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Figure 11. Box and whisker plots showing median (n=5), first quartile, third quartile, maximums and minimum daily 
loads for HIAS WWTW influent and effluents 
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Figure 12. Box and whisker plots showing median (n=5), first quartile, third quartile, maximum and minimum 
concentration of pharmaceuticals and hormones in sludges from HIAS WWTW 
 
Rambekk WWTW 
Daily median influent and effluent loads determined at Rambek WWTW were generally below 
4,225 mg day-1 (ciprofloxacin). Elevated median daily loads were also determined for 
amiloride (2,680 mg day-1), atorvastatin (2,952 mg day-1) and fexofenadine (2,306 mg day-1). 
Of those pharmaceuticals, the median effluent daily loads of amiloride were only slight 
reduced (5%), while atorvastatin loads were reduced by around 45%, ciprofloxacin by 8% and 
diclofenac by 50%. 
 
Five of the selected pharmaceuticals were detected in sludge from Rambekk (Figure 14). 
Amitryptyline was detected at a median concentration of 252 mg kg-1, azithromycin at 34 mg 
kg-1, clarithromycin at a median concentration of 8.4 mg kg-1, fexofenadine at a median 
concentration of 348 mg kg-1and lidocaine at 14 mg kg-1 in a single sample and <5 mg kg-1 in 
the other 4. 
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Figure 13. Box and whisker plots showing median (n=5), first quartile, third quartile, maximum and minimum daily 
loads for Rambekk WWTW influent and effluents 
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Figure 14. Box and whisker plots showing median (n=5), first quartile, third quartile, maximum and minimum 
concentration of pharmaceuticals in sludges from Rambekk WWTW 
 
Breivika WWTW 
Median influent and effluent loads of pharmaceuticals from Breivika were as high as 224,700 
mg day-1 (Ciprofloxacin; Figure 15). Elevated median loads were also observed for amiloride 
(66,284 mg day-1), atorvastatin (36,070 mg day-1), diclofenac (13,492 mg day-1), fexofenadine 
(36,482 mg day-1), lidocaine (11,589 mg day-1) and simvastatin (11,740 mg day-1). In general 
there was little difference between the median influent and effluent loads determined at 
Breivika WWTW. Since Breivika influent only receives basic treatment it is not surprising that 
there is little difference in loads.  
 
The contribution of UNN Tromsø to the overall loading is in general low, with the greatest 
contribution from ciprofloxacin at 0.5% of the total influent daily load. 
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Figure 15. Box and whisker plots showing median (n=5), first quartile, third quartile, maximum and minimum daily 
loads for Breivika WWTW influent and effluents 
 
3.2.2 Hormones 
VEAS WWTW 
The median influent daily load of E2 in VEAS WWTW influent was 45,600 mg day-1, which was reduced to 1,972 mg 
day-1 following treatment (Figure 6). The daily loads of EE2 were much lower at 0.11 and 0.01 mg day-1 for influent 
and effluent respectively. As is shown in Figure 6 there is a significant reduction in the E2 and EE2 loads following 
treatment. The median sludge concentration of E2 was 1 ng g-1 and EE2 was 0.33 ng g-1 ( 
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Figure 9).  
 
 
 
HIAS WWTW 
The median influent daily load of E2 in HIAS WWTW influent was 345 mg day-1, which was 
reduced to 7 mg day-1 following treatment (Figure 7). The daily loads of EE2 were much lower 
at 0.23 and 0.01 mg day-1 for influent and effluent respectively. As with VEAS WWTW there is 
a significant reduction in the E2 and EE2 loads following treatment (Figure 7). The median 
sludge concentration of E2 was 2.9 ng g-1 and EE2 was 0.8 ng g-1 (Figure 11).  
 
Rambekk WWTW 
Unfortunatley no data are available on the levels of E2 and EE2 in Rambekk influent. Median 
daily effluent loads were 66 and 0.07 mg day-1 respectivley for E2 and EE2. These are in a 
similar range to the other WWTW effluents analysed in this study. The median sludge 
concentration of E2 was 1.1 ng g-1 and EE2 was 0.9 ng g-1 ( 
 
 
 
 
 
 
 
 
 
 
Figure 13). 
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Breivika WWTW 
The median influent daily load of E2 in Breivika WWTW influent was 1230 mg day-1, which was 
reduced to 1088 mg day-1 following treatment (Figure 8). The daily loads of EE2 were much 
lower at 0.025 and 0.021 mg day-1 for influent and effluent respectively. Unlike with the 
other WWTWs that are fitted with much more advanced treatment than Breivika there is little 
reduction in the hormone loads (Figure 8). 
 
 
3.3 Inner Oslofjord 
3.3.1 Pharmaceuticals 
None of the 19 pharmaceuticals was detected in the Oslofjord surface water and sediment 
samples collected. Very few of the biota samples collected from Oslofjord contained 
detectable concentrations of the selected pharmaceuticals. Two samples of cod liver 
contained levels of amiloride (30 and 41 μg g-1), while all samples of shrimp from Oslofjord 
contained amiloride (18-57 (median=29) μg g-1). A previous screening study in 2008 showed 
the occurrence of certain pharmaceuticals  (naproxen, morphine and carbamazepine) in 
surface waters from Oslofjord up to 400 m from the point of discharge. Many of the 
pharmaceuticals detected in the discharged effluent were not detected in the receiving 
environment and this is also the case in the present study. This suggests that the selected 
compounds are sufficiently labile to be transformed following release into the fjord and/or 
there is sufficient dispersion to reduce their concentrations to below that, which is 
detectable. 
 
3.3.2 Hormones 
E2 was detected in all 5 surface water samples from Oslofjord at concentrations of between 
0.2 and 0.25 ng L-1. EE2 was detected in a single surface water sample at 0.007 ng L-1. E2 was 
detetcted in 2 of the 5 sediment samples at concentrations of 0.09 and 0.23 ng g-1. EE2 was 
not detected in Oslofjord sediments. E2 was detected in a single cod liver sample at 0.55 ng 
g-1, in a single herring sample at 0.21 ng g-1 and in all blue mussel samples at concentration of 
between 0.15 and 0.29 ng g-1. None of the shrimp samples contained E2. EE2 was detected in 
a single herring sample at a concentration of 0.04 ng g-1 and in 3 of the 5 blue mussel samples 
at concentrations of between 0.007 and 0.02 ng g-1. No other biota samples contained 
detectable concentrations of EE2. 
 
3.3.3 Vitellogenin levels in cod plasma 
VTGg was detected at low concentrations in the blood plasma of male cod (median 8.95 ng 
ml-1; Figure 16). The ICES BAC for male cod has been established at 2,300 ng ml-1 (ICES SGIMC, 
2012). This is almost 3 fold higher than the median value for male cod caught in Oslofjord and 
indicates no response to estrogens. The median VTG concentration for female cod was also 
low (15.87 ng ml-1) and most likely reflects the natural reproductive stage of the female cod 
sampled.  
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Figure 16. Vitellogenin concentrations in blood plasma samples taken from Atlantic cod from the Oslo fjord (median, 
quartiles, 10/ 90 percentiles, ng/ ml, F – female n=7, M – male n = 3). 
 
3.3.4 Histological evaluation of cod gonads 
A table was developed to score the gonadal development of female (Table 7) and male (Table 
8), Atlantic cod. Results of the histological evaluation of the gonads are reported in Table 9 
for the female fish and Table 10 for the male fish. In general, all cod were caught after they 
had spawned. Gonad stages were either spent (stage 5) or spent – ripening (stage 6). No 
particular histopathological conditions were found in general in this group of fish and a few 
females (n=3) showed a low degree of granulomatous inflammation. 
 
Table 7. Summary of reproductive stages of female Atlantic cod 
Reproductive stage Description 
1. Immature 
(small growth) 
Ovary wall thin. 
Oocytes vary from small (20 µm) with pale 
uniform cytoplasm to larger with basophilic 
cytoplasm apart from ølight ring of mitochondria 
around nucleus. Oocytes up to about 130 µm in 
diameter are irregular in outline, then round. 
Several nucleoli at periphery of nucleus – 
perinuclear stage PN. 
 
Ring of mitochondria moves away – 
circumnuclear ring stage CNR.   
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2. Mature Ripening 1 
(major growth starts) 
 
Zona radiata (ZR) appears as eosinophilic ring. 
Cortical alveoli appear in peripheral cytoplasm – 
CA 
 
 
* Image is from stage 5, to show oocytes in stage 
of major growth but not the characteristics of 
the ovary 
3. Ripening 2 
(early and late vitellogenesis) 
 
Yolk droplets YD first appear as small inclusions 
between vesicles, then enlarge and fill whole 
cytoplasm, restricting CA to periphery. Zona 
radiate widens and forms two layers in which 
radial striations can be seen. Irregular outlines of 
nucleus, nucleoli detached from periphery  
 
* Image is from stage 6 (spent ripening), to show 
oocytes in stage of vitellogenesis but not the 
characteristics of the ovary 
4. Ripe and Spawning Oocytes hydrates in batches. Yolk as homogenous 
mass. 
5. Spent 
 
 
Empty follicles (post ovulatrory follicles POF) 
and a few atretic hydrated oocytes. Small 
oocytes: formation of zona radiata, CA 
CNR 
PN 
POF CA 
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6. Spent – Ripening 
 
6*. Resting 
(see stage 5) 
Oocytes start vitellogenesis, empty follicles but 
no atretic hydrated oocytes 
 
 
 
 
 
Larger oocytes in CNR stage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.  Summary of reproductive stages of male Atlantic cod 
Reproductive stage  Description 
1. Immature Wall thin. 
Spermatogonia present single or in small groups  
YD 
CNR 
CA 
POF 
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2. Mature Ripening 1 
 
Cysts of spermatocytes form 
3. Ripening 2 All stages of development. Earlier stages along 
distal edge. In later stages cysts containing 
mature spermatozoa break down and coalesce to 
form tubules filled with spermatozoa, but lined 
with developing cysts. Few spermatozoa in large 
efferent ducts near mesochrium  
4. Ripe and Spawning All tubules and efferent ducts packed with 
spermatozoa. Few developing cysts left in early 
part of stage. Single or small groups 
spermatogonia in lining of tubules will give rise to 
SZ in next spawning season. 
5. Spent Tubules contain SZ. But few in large efferent 
ducts near mesochrium. Spermatogonia in distal 
part of testis 
SG 
SC 
SG 
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6. Spent – Ripening 
 
 
6*. Resting 
7.  
Cysts of spermatogonia SG and spermatocytes SC 
form in distal part of testis, SZ visible in proximal 
part 
 
 
 
 
 
 
Distally only spermatogonia SG present. SZ may 
still be present in efferent ducts 
 
 
Table 9. Results for female cod 
Fish code n 1 3 5 6 7 9 10 
Stage 5 6 6 5 6 5 6 
Increased oocyte atresia        
Perifollicular cell 
hyperplasia/hypertrophy 
       
Decreased vitellogenesis        
Changes in gonadal staging        
Interstitial fibrosis        
Egg debris in the oviduct        
Increased vascular or 
interstitial proteinaceous 
fluid 
       
Granulomatous 
inflammation 
 1    3 1 
Parasite        
Postovulatory follicles 1 1 1 3 2 3 1 
Atretic follicles        
mmc  1    1 2 
Blank: No observed occurrence. 
SG 
SG 
SC 
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Table 10. Results for male cod 
Fish code n  2 4 
Stage 5/6 2/6* 
Increased proportion of spermatogonia    
Presence of testis-ova    
Increased testicular degeneration (apoptotic)   
Interstitial (Leydig) cell hyperplasia/hypertrophy   
Decreased proportion of spermatogonia   
Interstitial fibrosis    
Increased vascular or interstitial proteinaceous fluid 2  
synchronous gonad development   
Altered proportions of spermatozoa or spermatocytes   
Gonadal staging    
Granulomatous inflammation  1 
Parasite   
Blank: No observed occurrence. 
3.4 Lake Mjøsa 
3.4.1 Pharmaceuticals 
None of the 19 pharmaceuticals was detected in the Lake Mjøsa surface water, sediment or 
biota samples collected.  
 
3.4.2 Hormones 
E2 was not detected in any of the surface water samples from Lake Mjøsa, while EE2 was 
detected in a single surface water sample at 0.013 ng L-1. Neither E2 nor EE2 were detected 
in Lake Mjøsa sediment. E2 was detected in 7 of the trout livers at concentrations of between 
0.01 and 0.32 ng g-1, whilst EE2 was below the LOD. E2 was detected at concentrations of 
between 0.02 and 0.03 in 3 of the 5 European smelt samples, in 4 out of 5 vendance at 
concentrations of between 0.05 and 0.12 ng g-1, and in 4 out of 5 of the Mysis samples at 
between 0.01 and 0.04 ng g-1. EE2 was not detected in any of these samples. 
 
3.4.3 Vitellogenin in trout plasma 
Vitellogenin (VTG) was detected at low concentrations (median 8.75 ng ml-1; Figure 17) in 
blood plasma samples of the two male brown trout and was indicative of typical low 
background concentrations in male fish. Although species-specific ICES background 
assessment criteria (BAC) are not currently available for brown trout with respect to VTG, 
BAC values are available for cod and flounder. In these cases a BAC of 2,300 ng ml-1 VTG and 
1,300 ng ml-1 VTG for male cod and flounder respectively are reported (ICES SGIMC, 2011). 
Therefore, VTG levels in male fish >1,300 ng ml-1 would be needed to indicate an estrogenic 
response, which did not occur in the present screening. However, only 2 males were sampled 
of the 10 fish collected. As expected, female VTG concentrations were markedly higher 
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(median 1,522 ng ml-1) than the males. These VTG concentrations were within the typical 
range reported in reference brown trout populations (Bjerregaard et al., 2006). 
   
Figure 17. Vitellogenin concentrations in blood plasma samples taken from brown trout from lake Mjøsa (median, 
quartiles, 10/ 90 percentiles, ng/ ml, F – female n= 8, M – male n=2). 
 
 
3.4.4 Histological evaluation of trout gonads 
A table is also presented to report the scoring of gonad development and abnormalities from 
trout (Table 11). The results of the histological evaluation of trout gonads are reported for 
the female fish as no male fish were caught (Table 12). As regards trout, half of the 
individuals were on stage 2 (ripening) and the remaining were on stage 4 (spent). Also in this 
case, almost no abnormalities were observed in the fish gonads. 
 
Table 11. Reproductive stages of follicles in female trout 
Reproductive stage of female trout  Description 
1. Immature or Previtellogenic follicles 
(small growth) 
 
Ovary wall thin. 
Oocytes vary from small (10-20 µm) with pale 
uniform cytoplasm to larger with basophilic 
cytoplasm apart from light ring of 
mitochondria around nucleus. Oocytes up to 
about 130 µm in diameter are irregular in 
outline, then round. Several nucleoli at 
periphery of nucleus – perinuclear stage PN. 
Ring of mitochondria moves away – 
circumnuclear ring stage CNR. 
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2. Ripening: Vitellogenic follicles Exogenous yolk formation YF – eosinophilic 
yolk granules, migrate from periphery to the 
centrum. Zona radiata and granulosa increase  
3. Ripe and Spawning – mature follicles Oocytes hydrates in batches. Yolk as 
homogenous mass. 
4. Spent 
 
Empty follicles (post ovulatrory follicles POF) 
and a few atretic hydrated oocytes AHO.  
* microphages and fibroblasts (fibrous capsule) 
5. Resting  
Blank: No observed occurrence. 
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Table 12. Results from female trout   
Fish code n test * ** *** **** ***** MØ6/5 bad bad bad bad 
Stage 4 2 2 2 2 2 2 4 4 4 4 
Increased oocyte atresia 3           
Perifollicular cell 
hyperplasia/hypertrophy 
           
Decreased vitellogenesis            
Changes in gonadal staging            
Interstitial fibrosis 3           
Egg debris in the oviduct            
Increased vascular or interstitial 
proteinaceous fluid 
           
Granulomatous inflammation     1       
Parasite            
Postovulatory follicles            
Atretic follicles            
mmc   3         
Blank: No observed occurrence. 
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4. Environmental Risk 
EU generated environmental quality standards (EQS) are available for three of the selected 
substances in surface waters; diclofenac (100 ng L-1), E2 (0.4 ng L-1) and EE2 (0.035 ng L-1). 
None of the surface water samples collected contained levels of these compounds above the 
EQS. For the remaining compounds all were below LoDs that were below available predicted 
no-effect concentrations. This suggests that the risks to the two selected recipients from the 
current loads of pharmaceuticals being released are low. 
 
A crude assessment of the levels detected in sludges was performed based on a previous 
assessment of contaminants in sludges applied on Norwegian soils (VKM, 2009). For two of the 
pharmaceuticals screened there are available PNECs for agricultural soils (atorvastatin 11 ng 
g-1; ciprofloxacin 26 ng g-1). Since the levels in sludges does not exceed these levels for 
agricultural soils then the risk is considered low. In the absence of published PNEC for a 
number of the selected pharmaceuticals a cut off of 100 ng g-1 was used as previously 
reported by Eriksen et al. 2009. Of the screened pharmaceuticals only amitriptyline and 
fexofenadine exceed this cut-off and it is recommended that further work be performed to 
evaluate the potential risks posed to agricultural soils from the occurrence of these two 
pharmaceuticals. 
 
The low levels of the hormones detected in sludges, combined with rapid biodegradation 
rates suggest that their occurrence is unlikely to pose a risk to the environment when land 
applying sludges (Clarke & Smith, 2011).  
 
5. Recommendations 
One major challenge in screening for the occurrence of pharmaceuticals in the environment is 
the large number of pharmaceuticals used in society and selecting those to study. Here and in 
previous screening reports we have evaluated the occurrence of a few pharmaceutical 
compounds, typically prioritised based on their volume of use, previous occurrence in the 
environment and potential to cause harm. Such an approach is useful but may not necessarily 
identify the few pharmaceuticals that may occur in receiving environments. Since Norway has 
a very good prescription register (Norwegian Prescription Database; www.norpd.no) and there 
is a clear link between WWTW influent concentrations and the amounts excreted it is possible 
to estimate, with relatively good confidence, the levels expected to be present in influent 
samples. In addition the advent of high-resolution mass spectrometric (HRMS) analysis has 
facilitated the potential to qualitatively screen for a large number of compounds in a single 
analysis, so-called suspect screening. We therefore propose that future screening of 
pharmaceuticals should use an informed suspect screening approach where firstly an 
evaluation as to the levels expected to be present in WWTW influent, based upon prescription 
data, to ensure detectable levels are likely to be present, followed by HRMS suspect 
screening of sources (influents and effluents) and immediate receiving waters. We 
recommend that biota samples should only be analysed for those pharmaceuticals known to 
occur in the receiving environment. This would form part of a tiered approach where firstly 
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sources and receiving waters would be suspect screened by HRMS, those compounds shown to 
be present quantified and finally determined in biota samples. Such an approach would allow 
a much broader coverage of different pharmaceuticals whilst focusing efforts on first 
establishing sources before looking for bioaccumulation and occurrence in biota. This we 
believe would be an improved use of resources whilst providing a more robust assessment of 
the potential hazard posed by the occurrence of pharmaceuticals in the environment.    
 
6. Conclusions 
Wastewater effluent from three Norwegian hospitals was shown to contain elevated loads of 
selected pharmaceuticals (i.e. amiloride, amitriptyline, amlodipine, atorvastatin, 
azithromycin, ciprofloxacin, clarithromycin, diclofenac, fexofenadine, hydrochlorothiazide, 
lidocaine and simvastatin). Typically the overall contribution, based on median daily loads, to 
the receiving wastewater treatment works was < 0.28% for Ullevål, <10% for SI Hamar and <6% 
or UNN Tromsø. 
 
Treated wastewater from four different WWTWs was shown to contain elevated loads of 
selected pharmaceuticals. Median daily loads were as high as 2.4 x 106 mg day-1 for certain 
pharmaceuticals (i.e. ciprofloxacin and fexofenadine). Effluent median loads of certain 
pharmaceuticals (i.e. atorvastatin, ciprofloxacin, diclofenac) and hormones were reduced 
when compared to influent loads, while median daily loads of other pharmaceuticals (i.e. 
amiloride, amitriptyline, azithromycin, clarithromycin, fexofenadine, lidocaine, simvastatin) 
were higher or similar in the treated effluent than influent. 
 
Median sludge concentrations ranged from between <2.5 and 415 ng g-1 with the following 
selected pharmaceuticals detected; amitriptyline; azithromycin, clarithromycin, 
fexofenadine, lidocaine. Hormone sludge concentrations were typically low (<1 ng g-1).  
 
Few residues of the discharged pharmaceuticals were detected in surface water, sediment 
and biota samples from the recipients of Oslofjord and Lake Mjøsa. 
 
Histopathological analysis of gonads and plasma vittellogenin levels in cod and trout gonads 
from Oslofjord and Lake Mjøsa respectively showed no effects attributable to the low levels 
of steroid hormones being discharged from WWTWs. 
 
The overall risk to the Norwegian aquatic environment from inputs of pharamceuticals is low 
with the levels determined below published EQS and PNEC values. For example, the EU Watch 
List pharmaceutical diclofenac and hormones E2 and EE2 were below the EQS. The risks to 
agricultural soils from the levels determined in sludges was also deemed to be low, however 
the absence of SoilPNEC for amitriptyline and fexofenadine suggests that further work should be 
performed on these two pharmaceuticals with respect to their occurrence. 
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